샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794516

세계의 신경근 질환 치료학 시장

Neuromuscular Disease Therapeutics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 273 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 신경근 질환 치료학 시장은 2030년까지 316억 달러에 달할 전망

2024년에 136억 달러로 추정되는 세계의 신경근 질환 치료학 시장은 2024-2030년의 분석 기간에 CAGR 15.0%로 성장하며, 2030년에는 316억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 생물제제는 CAGR 16.6%를 기록하며, 분석 기간 종료시에는 237억 달러에 달할 것으로 예상됩니다. 저분자 분야의 성장률은 분석 기간 중 CAGR 11.0%로 추정됩니다.

미국 시장은 37억 달러로 추정되는 한편, 중국은 CAGR 20.2%로 성장할 것으로 예측

미국의 신경근 질환 치료학 시장은 2024년에 37억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 69억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 20.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 10.9%와 13.6%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.0%로 성장할 것으로 예측됩니다.

세계의 신경근 질환 치료학 시장 - 주요 동향과 촉진요인 정리

신경근육질환 치료가 다시 주목받는 이유는 무엇인가?

신경근 질환에는 근이영양증, 근위축성측색경화증(ALS), 척수성 근위축증(SMA), 중증 근무력증 등 근육과 근육을 지배하는 신경의 기능을 손상시키는 질환군이 포함됩니다. 이러한 질병에 대한 관심이 높아진 것은 진단율 증가와 유전적, 분자적 기반에 대한 이해의 확대에서 비롯된 것입니다. 신생아 선별검사와 유전자 검사를 통해 더 많은 사례를 조기에 발견할 수 있게 됨에 따라 효과적인 치료 개입에 대한 수요가 빠르게 증가하고 있습니다.

최근까지 대부분의 치료 옵션은 증상 관리와 지지요법에 국한되어 있었습니다. 그러나 유전자 치료, 안티센스 올리고뉴클레오티드, 효소 보충 전략 등의 기술 혁신으로 치료법은 크게 변화하고 있습니다. 이러한 발전은 신경근육질환의 근본 원인을 타겟팅하고, 완화적 접근에서 질환의 변형적 해결로 패러다임을 전환하고 있습니다. 희귀질환 및 희귀질환 치료제 개발에 대한 규제 특혜는 새로운 치료법 연구를 더욱 가속화시키고 있습니다.

과학적 혁신은 어떻게 치료 환경을 변화시키고 있는가?

분자생물학 및 표적 전달 시스템의 획기적인 발전으로 신경근육 기능 장애를 유발하는 유전자 및 단백질 결함을 치료할 수 있는 치료법을 개발할 수 있게 되었습니다. 척수성 근위축증에 사용되는 것과 같은 유전자 치료는 중요한 유전자의 기능을 회복하거나 대체하는 것을 목표로 하며, 한 번의 투여로 장기적인 효과를 가져옵니다. RNA 수준에서 유전자 발현을 변화시키도록 설계된 안티센스 요법은 기능성 단백질의 생산을 촉진하여 뒤쉔형 근이영양증과 같은 질환을 치료하는 데 있으며, 인기를 끌고 있습니다.

다른 새로운 접근법으로는 신경근 전달 촉진, 면역에 의한 신경 손상 감소, 신경근 접합부 안정화를 목적으로 하는 모노클로널 항체 및 저분자 등이 있습니다. 또한 줄기세포 연구와 신경근육 재생의료도 연구 중이지만, 대부분 임상 초기 단계에 머물러 있습니다. 치료 전략의 정확도가 높아짐에 따라 환자 간 질병 진행의 편차를 해결하기 위해 병용 치료와 개별화된 요법이 평가되고 있습니다.

의료 시스템과 규제기관은 시장의 진화에서 어떤 역할을 하는가?

의료제도와 정책 프레임워크는 신경근육질환 치료제에 대한 접근과 상환을 형성하는 데 중요한 역할을 합니다. 유전자 치료제와 생물제제는 고가의 복잡한 물류가 필요하므로 가격 책정, 승인 일정, 장기적 결과 추적이 점점 더 까다로워지고 있습니다. 정부와 지불자는 혁신과 경제성의 균형을 맞추기 위해 결과 기반 상환 모델과 실제 데이터 모니터링을 모색하고 있습니다.

또한 공공기관, 연구기관, 생명공학 기업 간의 파트너십이 파이프라인의 확장을 촉진하고 있습니다. 신속한 승인 경로, 패스트트랙 지정, 희귀질환 치료제 특혜를 통해 더 많은 후보물질이 더 빨리 시장에 출시되고 있습니다. 그러나 특히 종단적 데이터가 부족한 신규 치료제의 경우, 승인 후 사후 감시와 장기 안전성 평가가 필수적으로 요구되고 있습니다. 또한 희귀 신경근육질환의 임상연구와 접근 전략을 지원하기 위해 국경을 초월한 공동연구와 환자 등록의 일원화도 개발되고 있습니다.

신경근육질환 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

유전자 검사 및 바이오마커 검사의 가용성이 확대됨에 따라 보다 빠르고 정확한 진단이 가능해져 질병 초기 단계의 치료 개입을 직접적으로 지원할 수 있게 되었습니다. 유전자 치료 플랫폼, 안티센스 기술, 정밀 생물제제의 발전으로 새로운 치료 옵션이 생겨나고 있으며, 그 중 상당수는 질병의 근본적인 메커니즘을 다루고 있습니다. 희귀질환 연구에 대한 자금 지원 증가와 유리한 규제 정책으로 인해 신약개발과 국제 공동 임상시험이 활발히 진행되고 있습니다. 환자 인식 증가, 지원 단체의 참여, 의료 인프라의 개선도 표적 치료제에 대한 수요를 촉진하고 있습니다. 신경근육질환의 신생아 선별검사의 보급과 전달 기술의 향상으로 치료법의 혁신과 시장의 성장을 더욱 촉진하고 있습니다.

부문

유형(생물제제, 저분자 제제), 최종사용자(병원 최종사용자, 클리닉 최종사용자, 기타 최종사용자)

조사 대상 기업의 예

  • Alexion Pharmaceuticals
  • Amicus Therapeutics
  • Avidity Biosciences
  • Aquestive Therapeutics
  • Argenx SE
  • BioMarin Pharmaceutical
  • Biogen Inc.
  • Catalyst Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Roche(see F. Hoffmann-La Roche)
  • Sarepta Therapeutics Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co. Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • Zydus Lifesciences Ltd.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Neuromuscular Disease Therapeutics Market to Reach US$31.6 Billion by 2030

The global market for Neuromuscular Disease Therapeutics estimated at US$13.6 Billion in the year 2024, is expected to reach US$31.6 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$23.7 Billion by the end of the analysis period. Growth in the Small Molecules segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 20.2% CAGR

The Neuromuscular Disease Therapeutics market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.9 Billion by the year 2030 trailing a CAGR of 20.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.0% CAGR.

Global Neuromuscular Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Is There Renewed Focus on Treating Neuromuscular Diseases?

Neuromuscular diseases encompass a group of disorders that impair the functioning of muscles and the nerves controlling them, including conditions such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and myasthenia gravis. Growing attention toward these conditions stems from both rising diagnosis rates and expanded understanding of their genetic and molecular underpinnings. As more cases are detected early through newborn screening and genetic testing, the demand for effective therapeutic interventions has grown rapidly.

Until recently, most treatment options were limited to symptom management or supportive care. However, innovations in gene therapy, antisense oligonucleotides, and enzyme replacement strategies are changing the therapeutic landscape. These advancements are targeting the root causes of neuromuscular conditions, shifting the paradigm from palliative approaches to disease-modifying solutions. Regulatory incentives for rare diseases and orphan drug development are further accelerating research into novel treatments.

How Are Scientific Innovations Reshaping the Treatment Landscape?

Breakthroughs in molecular biology and targeted delivery systems have enabled the development of therapies that can address defective genes or proteins responsible for neuromuscular dysfunction. Gene therapies, such as those used for spinal muscular atrophy, aim to restore or replace the function of critical genes, offering long-term benefits from a single dose. Antisense therapies, designed to alter gene expression at the RNA level, are gaining traction in treating conditions like Duchenne muscular dystrophy by promoting production of functional proteins.

Other novel approaches include monoclonal antibodies and small molecules aimed at enhancing neuromuscular transmission, reducing immune-mediated nerve damage, or stabilizing neuromuscular junctions. Stem cell research and neuromuscular regenerative medicine are also under exploration, although many remain in early clinical stages. As therapeutic strategies grow more precise, combination treatments and personalized regimens are being evaluated to address disease progression variability among patients.

What Role Do Healthcare Systems and Regulatory Bodies Play in Market Evolution?

Health systems and policy frameworks are playing a vital role in shaping access and reimbursement for neuromuscular disease therapies. Due to the high cost and complex logistics of gene and biologic therapies, pricing, approval timelines, and long-term outcome tracking have come under increased scrutiny. Governments and payers are exploring outcomes-based reimbursement models and real-world data monitoring to balance innovation with affordability.

Additionally, partnerships between public agencies, research institutions, and biotechnology firms are fostering pipeline expansion. Accelerated approval pathways, fast-track designations, and orphan drug incentives are helping more candidates reach the market faster. However, post-approval surveillance and long-term safety evaluations are becoming essential, especially for novel treatments with limited longitudinal data. Cross-border collaborations and centralized patient registries are also being developed to support clinical research and access strategies for rare neuromuscular conditions.

Growth in the neuromuscular disease therapeutics market is driven by several factors.

Expanding availability of genetic and biomarker testing is enabling earlier and more accurate diagnosis, directly supporting therapeutic intervention at earlier disease stages. Advances in gene therapy platforms, antisense technologies, and precision biologics are generating new treatment options, many of which address the disease’s root mechanisms. Increased funding in rare disease research, along with favorable regulatory policies, is encouraging drug development and global clinical trials. Rising patient awareness, advocacy group engagement, and improvements in care infrastructure are also boosting demand for targeted therapeutics. Broader adoption of newborn screening for neuromuscular disorders and improvements in delivery technologies are further supporting therapeutic innovation and market growth.

SCOPE OF STUDY:

The report analyzes the Neuromuscular Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Biologics, Small Molecules); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Alexion Pharmaceuticals
  • Amicus Therapeutics
  • Avidity Biosciences
  • Aquestive Therapeutics
  • Argenx SE
  • BioMarin Pharmaceutical
  • Biogen Inc.
  • Catalyst Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Roche (see F. Hoffmann-La Roche)
  • Sarepta Therapeutics Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co. Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Neuromuscular Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neuromuscular Disorders Drives Demand for Targeted Therapeutic Interventions
    • Advances in Gene Therapy Propel Development of Disease-Modifying Treatments for NMDs
    • Increased Regulatory Support for Rare Disease Therapies Strengthens Drug Development Pipeline
    • Expanding Clinical Trials for ALS, DMD, and SMA Accelerate Innovation in Neuromuscular Therapeutics
    • Emergence of RNA-Based Therapies Spurs Breakthroughs in Precision Neuromuscular Medicine
    • High Unmet Clinical Need in Pediatric Neuromuscular Disorders Expands Addressable Market
    • Growing Adoption of Monoclonal Antibodies Enhances Treatment Options for Autoimmune NMDs
    • Rise in Patient Advocacy and Funding Initiatives Drives Acceleration of Research and Commercialization
    • Advancements in Biomarker Discovery Support Early Diagnosis and Therapeutic Monitoring
    • Use of Digital Health and Wearable Devices Enables Real-Time Assessment of Disease Progression
    • FDA and EMA Orphan Drug Designations Generate Momentum for Neuromuscular Therapies
    • Adoption of Combination Therapy Approaches Expands Efficacy in Progressive NMD Cases
    • Rapid Growth in Personalized Medicine Drives Tailored Approaches to Neuromuscular Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neuromuscular Disease Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제